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Abstract
Background: Asthma can be difficult to diagnose, but bronchial provocation with methacholine, exercise or mannitol is helpful
when used to identify bronchial hyperresponsiveness (BHR), a key feature of the disease. The utility of these tests in subjects
with signs and symptoms of asthma but without a clear diagnosis has not been investigated. We investigated the sensitivity and
specificity of mannitol to identify exercise-induced bronchoconstriction (EIB) as a manifestation of BHR; compared this with
methacholine; and compared the sensitivity and specificity of mannitol and methacholine for a clinician diagnosis of asthma.
Methods: 509 people (6–50 yr) were enrolled, 78% were atopic, median FEV1 92.5% predicted, and a low NAEPPII asthma score
of 1.2. Subjects with symptoms of seasonal allergy were excluded. BHR to exercise was defined as a ≥ 10% fall in FEV1 on at least
one of two tests, to methacholine a PC20 ≤ 16 mg/ml and to mannitol a 15% fall in FEV1 at ≤ 635 mg or a 10% fall between doses.
The clinician diagnosis of asthma was made on examination, history, skin tests, questionnaire and response to exercise but they
were blind to the mannitol and methacholine results.
Results:  Mannitol and methacholine were therapeutically equivalent to identify EIB, a clinician diagnosis of asthma, and
prevalence of BHR. The sensitivity/specificity of mannitol to identify EIB was 59%/65% and for methacholine it was 56%/69%.
The BHR was mild. Mean EIB % fall in FEV1 in subjects positive to exercise was 19%, (SD 9.2), mannitol PD15 158 (CI:129,193)
mg, and methacholine PC20 2.1(CI:1.7, 2.6)mg/ml. The prevalence of BHR was the same: for exercise (43.5%), mannitol (44.8%),
and methacholine (41.6%) with a test agreement between 62 & 69%. The sensitivity and specificity for a clinician diagnosis of
asthma was 56%/73% for mannitol and 51%/75% for methacholine. The sensitivity increased to 73% and 72% for mannitol and
methacholine when two exercise tests were positive.
Conclusion: In this group with normal FEV1, mild symptoms, and mild BHR, the sensitivity and specificity for both mannitol and
methacholine to identify EIB and a clinician diagnosis of asthma were equivalent, but lower than previously documented in well-
defined populations.
Trial registration: This was a multi-center trial comprising 25 sites across the United States of America. (NCT0025229).
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Background
Asthma can be difficult to diagnose and no single symp-
tom or test should be used in isolation to make the diag-
nosis. A correct diagnosis is important in order for
patients to receive appropriate therapy [1]. Because bron-
chial hyperresponsiveness (BHR) is a hallmark of asthma,
bronchial provocation challenge tests (BPTs) with a vari-
ety of agents have been used to assist in its diagnosis [2-4].
Methacholine is a commonly used agent, delivered as a
wet aerosol. Methacholine acts directly on acetylcholine
receptors on smooth muscle causing contraction and air-
way narrowing. Methacholine has been reported to have a
high sensitivity to identify BHR and a negative test is often
used to exclude asthma [5,6].
Provocation tests that use indirect stimuli (e.g. exercise
and mannitol) have a high specificity for asthma [7] caus-
ing smooth muscle contraction by release of endogenous
mediators including prostaglandins, leukotrienes, and
histamine [8,9]. Evaporative water loss occurs in condi-
tioning the inspired air and causes exercise induced bron-
choconstriction (EIB) by inflammatory mediators of mast
cell origin [10,11]. Exercise is generally recognised as hav-
ing a low sensitivity to identify BHR; EIB is consistent with
a diagnosis of asthma [12] and responds to chronic treat-
ment with inhaled corticosteroids (ICS) and other drugs
used in the treatment of asthma [13-15].
A dry powder of mannitol has been developed as an indi-
rect BPT [16] and is available as a standardized test kit.
The test kit contains pre-filled mannitol capsules in esca-
lating doses and a hand-held dry powder inhaler device.
Safety and efficacy of mannitol as a BPT were established
in a large Phase III clinical trial in patients with asthma
and in healthy subjects [7].
The usefulness of mannitol as a BPT in subjects with signs
and symptoms of asthma but no clear diagnosis has not
been investigated previously. The aim was to study a large
population of subjects to compare the sensitivity and spe-
cificity of mannitol with methacholine to detect EIB as a
manifestation of BHR and to identify a clinician diagnosis
of asthma.
Subjects: inclusion criteria
Subjects aged 6–50 years (BMI < 35) with signs and symp-
toms suggestive of asthma according to the National Insti-
tute of Health (NIH) Questionnaire [17] but without a
firm diagnosis of asthma or an exclusion of the diagnosis
of asthma (e.g. had an equivocal diagnosis of asthma or
had been referred for further investigation of asthma-type
symptoms) were included. Subjects had at least Step 1
symptoms according to the NAEPPII asthma severity grad-
ing (symptoms ≤ 2 times per week; asymptomatic
between exacerbations; exacerbations of only a few hours
to a few days; and night time symptoms of ≤ 2 times per
month). They were required to have an FEV1 ≥ 70% of the
predicted value at the Screening Visit [18,19].
Subjects were excluded from participating in this study if
they: had any known other pulmonary disease; had
smoked more than 1 cigarette per week within the past
year or had a ≥ 10 pack year smoking history; had a respi-
ratory tract infection within the previous 4 weeks; had
been skin test positive to aeroallergens that were present
in the environment during the time of enrolment and
reported worsening of symptoms when exposed to these
aeroallergens during the study; had been diagnosed at
Screening Visit as definitively having asthma (95 to 100%
likelihood) or not having asthma (0 to < 5% likelihood);
had clinically significantly abnormal chest x-ray or ECG;
or had failed to observe washout of medications that
would interfere with BPT (including, but not limited to,
no use of corticosteroids within 4 weeks of the Screening
Visit).
Methods
The protocol was approved by a central institutional
review board. Each subject or parent gave informed con-
sent in writing. The study consisted of 5 visits to the clinic.
On the Screening Visit the following were assessed: eligi-
bility; demographic data; medical history; medications;
spirometry with reversibility (following 360 mcg of
albuterol); allergy skin test reactivity to common allergens
(positive test taken as 3 mm wheal). The NIH NAEPPII
questionnaire was answered and a score was assigned
[20]. Vital signs including blood pressure, heart rate, and
respiratory rate were measured in the sitting position and
an ECG performed. Based on this information, a respira-
tory physician assigned one of 6 diagnoses at this visit on
the basis of the likelihood of asthma as follows: asthma is
extremely likely or definite (95%–100% likelihood);
asthma is very likely (72.5 to < 95%); asthma is probable
(50 to < 72.5%); asthma is possible (27.5 to < 50%);
asthma is unlikely but cannot be excluded (5 to 27.5%);
and asthma is very unlikely (0-<5%). Those with 5 to 95%
likelihood were included in the study.
Visit 2 occurred 1–4 days after Visit 1 and within 2 hrs of
the time of Screening. Adverse events, medications, and
withholding times were reviewed (Table 1), and spirome-
try measured to confirm values on the screening day. This
was followed by a brief physical examination. Exercise
was performed with vital signs being measured before and
after exercise. At Visit 3, the procedures were the same as
Visit 2 and occurred within 1–4 days. At Visit 4, adverse
events and medications were reviewed, withholding times
were checked, and spirometry was performed to confirm
FEV1 was within 15% of Visit 1. The challenge agent wasRespiratory Research 2009, 10:4 http://respiratory-research.com/content/10/1/4
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either mannitol or methacholine, and the choice was ran-
domly determined. The time of the test was documented
for each challenge. Vital signs were measured in the sitting
position before and after the challenge test. Cough and
pulse oximetry were recorded during mannitol challenges.
Full spirometry was measured before and at 15 minutes
after completion of the mannitol challenge with FEV1
only being performed after each dose. ECG was per-
formed before and after mannitol challenge. Visit 5 was a
repeat of the procedures of Visit 4 with the reciprocal chal-
lenge being administered (either mannitol or metha-
choline). A respiratory physician then assigned one of the
diagnoses of likelihood of asthma evaluated at the Screen-
ing Visit, above. The NAEPII asthma severity grading score
was also re-evaluated at Visit 5 but not necessarily by the
same physician.
Bronchial provocation tests
Exercise challenge
Exercise was performed by running on a motorised tread-
mill whilst breathing medical grade dry air (20–25°C)
from a Douglas Bag [14]. Briefly exercise was ramped up
Table 1: Medications and other factors that may decrease bronchial hyperresponsiveness and their required withholding periods
FACTOR Withholding Period
Inhaled agents Short acting bronchodilators (isoproterenol, isoetharine, metaproterenol, albuterol, 
levalbuterol, terbutaline) (e.g. Proventil® or Ventolin®)
8 hr
Inhaled anticholinergics or combination products (e.g. Atrovent® or Combivent®) 1 week
Medium acting bronchodilators (ipratropium) 1 week
Long acting inhaled bronchodilators (salmeterol, formoterol) (e.g. Serevent® or Foradil®) 2 weeks
Inhaled corticosteroid/long acting inhaled bronchodilator combination (e.g. Advair®) 4 weeks
Oral bronchodilators Theophylline 24 hr
Intermediate theophylline 48 hr
Long acting theophylline 48 hr
Standard β-agonist tablets 24 hr
Long acting β-agonist tablets 48 hr
Corticosteroids There is no washout for topical steroids applied to skin unless they are high potency steroids 4 weeks
Other medications Hydroxyzine, cetirizine (and other antihistamines) 72 hr
Tiotropium bromide 72 hr
Nasals steroids 1 week
β-blockers 1 week
Cromolyn sodium 2 weeks
Nedocromil 2 weeks
Leukotriene modifiers 6 weeks
Foods Coffee, tea, cola drinks, chocolate (caffeinated foods) 12 hr
Strenuous exercise or exposure to cold air to a level that would be expected to interfere with challenges 12 hr
Tobacco 6 hrRespiratory Research 2009, 10:4 http://respiratory-research.com/content/10/1/4
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over two minutes to 80–90% predicted heart rate (220-
age) and then sustained for 6 minutes. The highest FEV1
was measured before and at 5, 10, 15 and 30 minutes after
exercise. The % fall in FEV1 was calculated by subtracting
the lowest value recorded after exercise (best of two
acceptable attempts at each time point) from the value
measured immediately before exercise and expressing it as
a percentage of the pre exercise value. A subject was
deemed positive if there was a fall of ≥ 10% in FEV1 at one
time point [2,3] on at least one of the two exercise chal-
lenges.
Mannitol challenge
The mannitol test was carried out as per the standard lab-
oratory protocol for this challenge test using the commer-
cially available mannitol test kit (known as Aridol™ or
Osmohale™ Pharmaxis Ltd, AUS) [7]. The FEV1 was meas-
ured 60 seconds after each mannitol dose (0, 5, 10, 20, 40,
80, 160, 160, 160 mg). The subjects were asked to exhale
completely before taking a controlled deep inspiration
from the device and to hold their breath for 5 seconds
then exhale through their mouth before removal of the
nose clip. Sixty seconds after inhalation of the 0 mg cap-
sule the FEV1 was measured in duplicate. The highest of
these values was taken as the baseline FEV1 and was used
to calculate the target FEV1 value that indicated a 15% fall
in response to the mannitol challenge. The test result
expressed is a PD15.
The procedure outlined above for the 0 mg capsule was
repeated for each dose step until a 15% fall in FEV1 was
achieved (or a 10% fall between consecutive doses) or the
cumulative dose of 635 mg had been administered.
Methacholine
Methacholine (Provocholine™, Methapharm CA) was
delivered from a nebulizer (DeVilbiss model 646) by the
dosimeter method [2]. The concentrations were: 0.0312,
0.0625, 0.125, 0.25, 0.5, 1, 2, 4, 8, 16 mg/mL. Each con-
centration required five inhalations from functional resid-
ual capacity to total lung capacity. Spirometry was
performed within 3 minutes. The response to metha-
choline was expressed as the concentration required to
provoke a 20% fall in FEV1 from the pre-challenge value
(PC20).
Bronchodilator
On Visit 1 a dose of 360–400 mcg of albuterol (salbuta-
mol) was administered and the FEV1 measured between
15 and 30 minutes. A positive test was defined as a 12%
increase in FEV1 above the baseline value.
Statistical testing
Results were expressed using univariate statistics includ-
ing means, standard deviations, ranges, and medians.
Mannitol and methacholine responses were log trans-
formed for calculation of the geometric means. The anal-
ysis plan specified a test of non-inferiority to be achieved
if the lower 95% credible limit for the adverse-event-free-
ratio (1-AERmannitol)/(1-AERmethacholine) exceeded 0.80.
Analysis
The sensitivity and specificity of a mannitol positive test
(defined as ≥ 15% fall in FEV1 ≤ 635 mg or a ≥ 10% fall in
FEV1 between consecutive doses) and a methacholine pos-
itive test (defined as PC20FEV1 ≤ 16 mg/ml) with respect to
EIB (defined as ≥ 10%, 15% or 20% fall in FEV1 after a
standardized treadmill run) and with respect to a clini-
cian's diagnosis of asthma at Visit 5 were calculated. Addi-
tional analyses were performed excluding those with a
mannitol test taking longer than 35 minutes because the
osmotic gradient will not progressively increase if the time
between doses is prolonged.
Safety data
Vital signs (including blood pressure, heart rate, and res-
piratory rate) using the intent-to-treat population (ITTP, n
= 391) and their changes during challenge tests are
described. The adverse events were tabulated following
each challenge test. The per-protocol population (PPP, n
= 375) included all subjects with no major protocol viola-
tions who completed all of the required challenge tests,
including methacholine and mannitol challenges.
In the protocol cough was identified as an adverse event if
it prevented the challenge from being completed in which
case it was documented as severe at the time of testing.
Blinding
A respiratory physician was to make the Clinician diagno-
sis at the final visit (Visit 5) with access to the data on the
exercise challenges, history, examination, skin tests, and
FEV1 reversibility but not the mannitol and methacholine
challenge test result. Site staff members performing man-
nitol and methacholine challenges were not provided
with other diagnostic information about the subject to
assure that there was no bias in the performance of these
tests. Mannitol and methacholine challenges were given
in a restricted randomization scheme that produced equal
numbers of each order.
To accomplish proper blinding, the mannitol and metha-
choline challenge team did not have access to the elec-
tronic case report form (eCRF) or to other physiological
data. Similarly, other site personnel did not have access to
the mannitol and methacholine challenge data. Mannitol
and methacholine challenge data were able to be reviewed
by the Data Manager at CompleWare Inc but they were
only provided to the Sponsor (Pharmaxis Ltd) at the end
of the study.Respiratory Research 2009, 10:4 http://respiratory-research.com/content/10/1/4
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Results
The disposition of the subjects is given in Figure 1. There
were 16 people in the ITTP who were not included in the
PPP. The data are given for the PPP unless otherwise stated
because it represents the results for all the subjects who
performed all the tests. The age distribution for 375 sub-
jects in the PPP are presented in Table 2. The characteris-
tics of the subjects are summarised in Table 3. There were
96 children and 279 adults (> 18 years); 51.5% female;
76.3% Caucasian, 8.3% Hispanic and 8.5% Black; with
near-normal baseline spirometry; with low NAEPPII
asthma score of 1.2 (SD 0.5); 78% atopic; and 7.5%
responding positively to a bronchodilator. Of the 375,
145 were considered by the respiratory physician to have
a 50% or more likelihood of having asthma at Visit 1.
There were 163 (43.5%) subjects who had a positive
response to exercise (Exc+) with a ≥ 10% fall in FEV1 on
at least one test; 119 recording this on the first exercise test
with 66 of these 119 recording a ≥ 15% fall in FEV1. There
were 168 (44.8%) subjects with a positive test to mannitol
(Mann+). Of these, 109 achieved a 15% fall in 635 mg
and the remaining achieved a positive test by a 10% fall in
FEV1 between consecutive doses. Seventy three percent
achieved this response within the first 6 doses of mannitol
(≤ 315 mg). There were 156 (41.6%) with a positive test
to methacholine (Mech+) with a PC20 ≤ 16 mg/ml, and
26% achieved this response within the first 6 concentra-
tions (≤ 1 mg/ml) being delivered. The percentile values
and median data for the positive responses are given in
Table 4.
Sensitivity and specificity of mannitol and methacholine
to identify a subject with different levels of severity of EIB
is given in Table 5. There was no significant difference
between mannitol and methacholine to identify EIB;
however, these agents did not necessarily identify the
same people and the agreement between the mannitol
and methacholine test results was 69%. Agreement for
mannitol and exercise was 62% and for methacholine and
exercise was 63%. The relationship between the reactivity
to mannitol expressed as log RDR and the reactivity to
exercise expressed as the maximum % fall in FEV1 was sig-
nificant but not strong (r = 0.256, p < 0.001, n = 312).
Maximum % fall in FEV1 to mannitol in relation to meth-
acholine (r = 0.41 p < 0.0001) in those positive and nega-
tive to exercise is illustrated in Figure 2. Forty-six (29%)
people had a fall ≥ 30% in FEV1 after methacholine, 2
(1.2%) after mannitol and 25 (15.3%) after exercise. The
mean maximum % fall (SD) in FEV1 after those with a
positive methacholine challenge was 27.7% ± (8.2) and
after a positive mannitol challenge was 16.1% ± (5.6). The
fall after mannitol was 19.2% ± (4) excluding those who
were positive due to a 10% fall between doses, and this
was the same as the fall after exercise19.1% (9.4). Sensi-
tivity and specificity of mannitol and methacholine to
identify Exc+ 10% in relation to symptoms score is sum-
marised in Table 6.
Mannitol had a sensitivity of 67% to identify a Mech+
PC20 of ≤ 16, 68% for ≤ 12, and 68% for ≤ 8 mg/ml and
a sensitivity of 77% to identify ≤ 4 mg/ml and 83% to
identify ≤ 2 mg/ml. Methacholine had a sensitivity of 62%
for identifying a Mann+ response. An Exc+10% on the
first test had a sensitivity of 62% to identify Exc+10% on
the second test. The receiver operator curves for mannitol
and methacholine in relation to identifying EIB is illus-
trated in Figure 3 and are almost identical for mannitol
and methacholine. The negative and positive predictive
values for mannitol and methacholine were close gener-
ally differing by 0.01 or less. Similarly the negative (0.64
and 0.65) and positive likelihood ratios (1.71 and 1.79)
were similar for mannitol and methacholine respectively.
There were 28 (7.5%) subjects in the per protocol popula-
tion who reversed at least 12% after a beta2 agonist. This
small group showed a sensitivity of mannitol and metha-
choline to identify EIB of 68.4% and 73.7% and a specif-
icity of 44.4% and 55.5% respectively.
Sensitivity and specificity for mannitol and methacholine
to identify a 10% fall after exercise in children and a clin-
ical diagnosis at Visit 5 is given in Table 7. Of the 375 PPP,
there were 240 (64%) identified as having a clinical diag-
nosis of asthma at Visit 5 (ClinDx5+) and 48% of these
had a likelihood of asthma (see definitions above) greater
than 50% assigned at Visit 1. Fifteen percent of the sub-
jects who received a clinical diagnosis of asthma were neg-
ative to all three challenges. Of the 135 who did not
receive a clinical diagnosis of asthma at Visit 5 (ClinDx5-
), 78% had a likelihood of asthma of less than 50%
assigned at Visit 1. Sensitivity and specificity of mannitol
to predict ClinDx5+ was 55% and 73%. The sensitivity for
mannitol rose to 73% when ClinDx5+ was associated
with two Exc+ 10% tests. The comparable sensitivity and
specificity for methacholine (PC20 ≤ 16 mg/ml) was 51%
and 75% and sensitivity rose to 72% when ClinDx5+ was
associated with two Exc+10% tests.
The positive and negative predictive values for mannitol
for a ClinDx5+ were 79% and 48% and for methacholine
they were 78% and 46%. There were 106 subjects negative
to mannitol, 118 negative to methacholine and 92 nega-
tive to exercise who were given a clinician diagnosis of
asthma at Visit 5. When the subjects who took longer than
35 min for a mannitol challenge were excluded, the sensi-
tivity of mannitol to identify a 95% risk of having asthma
as judged by the clinician was 76%. For methacholine this
equivalent value was 67%.Respiratory Research 2009, 10:4 http://respiratory-research.com/content/10/1/4
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Subject disposition Figure 1
Subject disposition.
Enrolled by site & 
recorded in 
electronic
case report form
n = 510
Safety:
Intent-to-Treat, 
Per Protocol & 
Safety 
Populations
n = 436 
Excluded from Safety, Efficacy Analyses: n = 74
• Inclusion/Exclusion: Elevated BMI (9) 
• Inclusion/Exclusion: Active Allergies (2)
• Inclusion/Exclusion: Smoking (2)
• Inclusion/Exclusion: Asthma Very Likely or Very Unlikely (19)
• Inclusion/Exclusion: Cannot perform spirometry (5)
• Inclusion/Exclusion: Abnormal or missing chest x-ray (2)
• Inclusion/Exclusion: Abnormal ECG (1)
• Inclusion/Exclusion: Baseline FEV1<70% Predicted (9)
• Withdrew Consent/Lost to Follow-up (15)
• Excess FEV1 variability (1)
• Adverse Event (2)
• Enrolment Closed (7) 
Excluded from Intent-to-Treat Analysis: n = 45
• Included in P+ but not in Per Protocol population because 
exercise challenge was inadequate and both exercise 
challenges were negative (29)
• Withdrew consent (5)
• Took prohibited drug (2)
• Excess FEV1 variability (1)
• Adverse Event (4)
• Enrolment closed (1)
• Inadequate spirometry (2)
• Inclusion/Exclusion: Asthma Very Likely (1) 
Intent-to-Treat Plus Population: n = 420
• Intent-to-Treat (391)
• Missed portion of exercise challenge, both negative (3)
• Inadequate exercise challenge, both negative (26)
Intent-to-Treat:
Intent-to-Treat & 
Per Protocol 
Populations
n = 391
Excluded from Per Protocol Analysis: n = 16
• Withdrew consent (5)
• Methacholine doses missed (5)
• Methacholine doses given out of order (1)
• Aridol challenge not completed (4)
• Inclusion/Exclusion: Antihistamine taken (1) 
Per Protocol Plus Population: n = 404
• Per Protocol (375)
• Missed portion of exercise challenge, both negative (3)
• Inadequate exercise challenge, both negative (26) 
Per Protocol:
Per Protocol 
Populations
n = 375Respiratory Research 2009, 10:4 http://respiratory-research.com/content/10/1/4
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The time to perform a positive mannitol test was signifi-
cantly shorter than a positive methacholine test by
approximately 25 min (19.9 min [SE 0.9] vs 44.5 min [SE
1.4]). In those Mech+ only it was 48.3 min (SE 1.7) and
for those Mann+ only it was 19.2 min (SE 1.3).
Time for recovery of FEV1 to 95% of baseline was similar
for all tests. Mannitol was 21.6 min (SD 9.0) vs. metha-
choline 21.06 min (SD 6.96); the maximum time for
recovery on the two exercise tests was 22.9 min (SD 13.7).
Median time for recovery after mannitol and metha-
choline was 19 min (interquartile range 17–24).
Sensitivity and specificity for methacholine to identify EIB
were considerably less consistent across the centres than
for mannitol. The between centre standard deviation for
the log odds ratio for methacholine and mannitol was
respectively 1.26 vs. 0.32 for sensitivity (p < 0.02) and
0.68 vs 0.47 (p = NS) for specificity. Thus there was signif-
icantly less variation in sensitivity of mannitol to identify
EIB between centres compared with methacholine.
The skin test results for the wide variety of allergies are
summarised in Table 8 for the per protocol population.
The percentage of subjects positive to one or more skin
tests for those Exc+ was 42.6%, for Mann+ it was 47.1%
Table 2: Demographics: Age distribution in the intent-to-treat, in the excluded and safety, and in the per-protocol populations.
Intent-to-Treat Excluded and Safety Per-Protocol
Age Number Percent Number Percent Number Percent
Total 391 509 375
6–7 6 1.5% 9 1.8% 6 1.6%
8–9 7 1.8% 11 2.2% 7 1.9%
10–11 20 5.1% 25 4.9% 19 5.1%
12–15 38 9.7% 48 9.4% 36 9.6%
16–18 44 11.3% 57 11.2% 43 11.5%
19–24 113 28.9% 135 26.5% 108 28.8%
25–30 69 17.6% 84 16.5% 68 18.1%
31–35 28 7.2% 44 8.6% 25 6.7%
36–40 31 7.9% 44 8.6% 29 7.7%
41–45 19 4.9% 25 4.9% 19 5.1%
46–50 16 4.1% 27 5.3% 15 4.0%
Table 3: Anthropometric data, forced expiratory volume in one second, and smoking history in the per protocol population.
Age (yr) BMI FEV1 (L) % Pred FEV1 Post BD FEV1 (L) Pack Yrs Ht (cm) Wt (kg)
Mean 24.3 24.4 3.32 93.6% 3.48 2.9 167.4 69.2
SD 10.2 4.5 0.82 10.0 0.87 2.8 13.1 18.4
Range 6–50 13.4–34.9 1.15–5.62 63.7–140.1 1.29–5.92 0–9 118–204.5 20–135.2
Median 22 24.1 3.24 93.3 3.32 2.5 167.6 69Respiratory Research 2009, 10:4 http://respiratory-research.com/content/10/1/4
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and for Mech+ it was 41.8%. It was higher in those achiev-
ing a ClinDx5+ 63.0%.
During mannitol challenges, frequency of cough was
monitored in 419 subjects. Of these 391 had cough (93%)
with 204 having occasional cough (49%) that did not
interfere with the challenge, 178 frequent cough (42%)
that delayed the administration of the next dose and 9
severe cough (2.1%) that caused the challenge to be
stopped and an adverse event to be recorded.
Vital signs changed as expected, with increased in systolic
and diastolic blood pressure, heart rate, and respiratory
rate associated with both exercise challenges. Trivial
increases in blood pressure were seen associated with
mannitol and methacholine challenges. Oxygen satura-
tion did not change appreciably with mannitol challenge
and only 3 subjects had > 3% reduction. Heart rate
increased slightly after mannitol challenge and decreased
slightly after methacholine challenge. Respiratory rate was
also largely unchanged with both mannitol and metha-
choline challenge.
Adverse events
All adverse events which commenced after the challenges
were reported by MedDRA System Organ Class and Pre-
ferred Term and tabulated (Table 9) There were more
adverse events on mannitol compared with methacholine
130 vs 89. The distribution across range of severity of
events was the same. There were 62 moderate adverse
events on mannitol and 35 on methacholine, with 9
severe ones on mannitol and 3 on methacholine. There
were no serious adverse events for any of the challenge
tests. Mannitol was non-inferior to methacholine in the
sense that the proportion of subjects who did not experi-
ence adverse events in the mannitol challenge was at least
80% of the proportion who did not experience adverse
events in the methacholine challenge (92.9%) as per the
statistical analysis plan.
Discussion
In these subjects with very mild symptoms suggestive of
asthma and good lung function, sensitivity and specificity
were equivalent for mannitol and methacholine to iden-
tify EIB and a clinical diagnosis of asthma. There were no
serious adverse events associated with the tests and both
were generally well tolerated.
Mannitol sensitivity to identify EIB was lower than that
previously reported in subjects with a definite diagnosis of
asthma [21,22]. The lower sensitivity of mannitol to iden-
tify EIB reported here is consistent with the mild EIB (50%
of subjects had falls in FEV1 ≤ 15%) documented in this
group who did not have a definite diagnosis of asthma.
The % fall in FEV1 in the asthmatics reported by Brannan
[21] was 40 ± 19% (SD) and by Munoz [22] it was 37% ±
16% (SD). In the study of Holzer [23] a PD15 to mannitol
had a sensitivity of 83% to identify EIB in a group of ath-
letes with a 25.4% ± 15% (SD) fall in FEV1 after eucapnic
voluntary hyperpnea, a surrogate challenge for EIB.
Table 4: Percentile and geometric mean values for bronchial provocation tests as well as maximum % fall for subjects with positive 
exercise challenges.
Percentiles
25th 50th 75th Geomean (95% CI)
Mann+ PD15 (mg) 72 234 374 158 (129,193)
Mech+ PC20 (mg/ml) 0.84 2.98 6.53 2.12 (1.7,2.64)
Exc+ % Fall 23.6% 15.5% 12.4% 19.1% (9.25)*
*Mean (SD)
The maximum percentage fall in FEV1 for mannitol and meth- acholine in subjects in the per-protocol population Figure 2
The maximum percentage fall in FEV1 for mannitol 
and methacholine in subjects in the per-protocol 
population.
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The sensitivity of mannitol to identify a Exc+ 20% fall in
FEV1 was > 80% when those with a prolonged mannitol
test time were excluded. Sensitivity of the mannitol to
detect a Exc+10% fall was also > 80% in those with an
asthma symptom severity score of 2 rather than 1,
although the numbers with this score were smaller.
Sensitivity and specificity of methacholine and mannitol
for a clinical diagnosis of asthma was equivalent in this
study, but the values were lower than those reported in
well-defined populations of asthmatic and healthy sub-
jects [7] and similar to those reported for epidemiological
studies [24-26]. In the children less than 18 yrs, however,
mannitol had a 18.5% higher specificity (81.4% vs
62.9%) for identifying a clinical diagnosis of asthma and
a 10% lower sensitivity (60.1% vs 70%) to identify EIB
compared with methacholine.
This lower than expected sensitivity for mannitol and
methacholine to identify EIB or a clinical diagnosis may
be explained by the relatively unusual nature of this group
of subjects who would not have qualified either for a clin-
ical study on asthmatic subjects or a study on healthy sub-
jects. The exclusion criteria required that the subjects not
be symptomatic to the allergens to which they demon-
strated atopy at the time of the study. This too is unusual
and may affect mast cell number and IgE status. There was
a lack of agreement between the clinical diagnosis and
response to the challenge tests in 27% of the subjects;
15% of subjects given a diagnosis of asthma were negative
to all three challenge tests and 12% with two or more pos-
itive challenge tests were deemed not to have an asthma
diagnosis at Visit 5. The dose of mannitol (PD15) or con-
centration of methacholine (PC20) in those who were pos-
itive in this study was consistent with the values reported
previously in clinically recognised asthmatics not taking
inhaled corticosteroids [27,28].
The prevalence of BHR identified by the three tests dif-
fered by only 3.2% (from 41.6% to 44.8%). This suggests
that the cut-off points used to define BHR were appropri-
ate. Further, the range of severity of BHR was similar for
all the tests with 50% being in the mild range for manni-
tol and exercise and 75% in the mild range for metha-
choline [2,29]. However it was not always the same
subject responsive to all the BPTs and only 17.9% of sub-
jects were positive to all three challenge tests. This proba-
bly reflects the natural variability of the test responses in
people with mild BHR and intermittent symptoms.
Some long-held beliefs about methacholine were not
upheld by the results of this study. Methacholine did not
Table 5: Sensitivity and specificity of challenge at different cut points for a positive test.
Exercise Positive Cut-Points – % fall from baseline 10% 15% 20%
Mannitol Sensitivity 58.6 69.4 78.6
n = 372 Specificity 65.2 62.0 60.8
Excluding those with challenge > 35 min Sensitivity 64.1 75.3 82.7
n = 319 Specificity 59.9 57.0 55.4
Methacholine 16 mg/ml Sensitivity 55.2 67.4 80.3
n = 375 Specificity 68.9 66.1 65.2
Table 6: Sensitivity and specificity to identify exercise-induced bronchoconstriction (EIB) in relation to the asthma severity score.
NAEPPII
Visit 1 Visit 5
A s t h m a  S e v e r i t y  S c o r e 0 1230123
N mann = 0 308 47 17 13 294 48 15
N mech = 0 310 48 17 14 296 48 15
Mannitol Sensitivity 56.6 75.0 60.0 50.0 55.1 78.3 66.7
635 mg Specificity 69.2 48.4 42.9 72.7 67.7 56.0 16.7
Methacholine Sensitivity 54.7 62.5 50.0 0.0 56.3 56.5 44.4
16 mg/ml Specificity 72.8 46.8 71.4 66.7 70.8 56.0 66.7Respiratory Research 2009, 10:4 http://respiratory-research.com/content/10/1/4
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have a higher sensitivity than exercise and mannitol to
identify BHR in this population, and the prevalence of
BHR was similar for all tests. Methacholine did not have a
high negative predictive value for a clinical diagnosis of
asthma. There were 118 subjects negative to methacholine
who were given a diagnosis of asthma at Visit 5. It was also
not uncommon for methacholine to miss EIB, and 73 of
the 163 subjects (45%) positive to exercise were negative
to methacholine, confirming previous findings in young
people with good lung function [30]. The sensitivity of a
positive response to the first exercise test to predict a pos-
itive response to the second test (62%) was the same as
the sensitivity of mannitol and methacholine to predict at
least one positive test to exercise. This low sensitivity
probably relates to the variability in the mild response to
exercise, particularly in those without symptoms of allergy
at the time of testing. By performing a second test, an extra
44 people were identified as having EIB. Care was taken in
this study to minimise the potential for variability, and
there was good overall agreement between the two exer-
cise test results; however, this was primarily due to the
number of negative exercise tests.
Only one exercise test and one time point of ≥ 10% was
required to be the 'gold' standard used for BHR. This cri-
terion may be interpreted by some investigators as not
strict enough because of the variability of the response to
exercise. However the value for sensitivity of mannitol to
identify EIB was relatively unchanged (59.8% vs 58.3%)
when only those subjects with two time points on one
exercise challenge were ≥ 10%, or one time point was
greater than ≥ 15%, were included in the analysis. The
value for sensitivity for methacholine however rose from
55.3% to 63.1% applying the same criteria.
There were 7.5% of subjects with a positive response to
bronchodilator at baseline who were not excluded at entry
on the basis of having a > 95% chance of having asthma,
presumably as the other evidence was not supportive. This
group of 28 showed a higher value for sensitivity of man-
nitol (68.4% vs 59%) and methacholine (73.7% vs 56%)
to identify EIB when compared with the entire popula-
tion.
Cockcroft [31] has found that methacholine sensitivity to
identify BHR of 4 mg/ml or more is lower using the
dosimeter method compared with the tidal breathing
method. The dosimeter method used here is one recom-
mended in the American Thoracic Society guidelines that
categorize BHR between 4–16 mg/ml as borderline [2], is
in common use, and delivery of the aerosol by this
method involves a similar inspired breathing pattern as
the mannitol with which it was being compared. We chal-
lenged to 16 mg/ml and, on the basis of the Cockcroft
Table 8: The frequency of positive skin tests (> 3 mm wheal) to a variety of allergens in the per protocol population (n = 375).
Cat Cockroach Dog Grass House Dust Mites Mold *Cedar Rag weed Other Weeds Trees
Positive 153 48 75 180 175 99 56 106 126 146
Tests done 363 299 363 336 347 363 145 298 323 328
% Positive 42.1 16.1 20.7 53.6 50.4 27.3 38.6 35.6 39.0 44.5
*Mountain Cedar
The receiver operating curve for mannitol and methacholine  to identify exercise-induced bronchoconstriction defined as  ≥ 10% fall in FEV1 from baseline at one time point after exer- cise on at least one of two exercise tests Figure 3
The receiver operating curve for mannitol and meth-
acholine to identify exercise-induced bronchocon-
striction defined as ≥ 10% fall in FEV1 from baseline at 
one time point after exercise on at least one of two 
exercise tests.
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Table 7: Children < 18 yrs (n = 115). Per protocol population
"Gold Standard" 10% Ex+ ClinDx5+
Mannitol Sensitivity 60.1 63.2
Specificity 58.5 81.4
Methacholine 16 mg/ml Sensitivity 70.0 66.2
Specificity 54.5 62.9Respiratory Research 2009, 10:4 http://respiratory-research.com/content/10/1/4
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observation, this may be equivalent to 8 mg/ml on the
tidal breathing method. A PC20 of > 8 mg/ml is the value
for normality illustrated in the 2007 GINA guidelines [32]
and stated by the British Thoracic Society [33].
This study included steroid naïve subjects who were con-
sidered to have a greater than 5% and less than 95% prob-
ability of having asthma at entry based on spirometry,
response to bronchodilator, symptoms, history and skin
tests. The clinical value in comparing different diagnostic
tools, such as the challenge tests used here, cannot really
be judged because there is no gold standard test for the
diagnosis of asthma. The strategy used here for a 'gold
standard' for the diagnosis of asthma was to have a respi-
Table 9: Adverse events following bronchial provocation and those not related to challenge in the safety population.
System Organ Class Preferred Term 1st Exc# 2nd Exc Mann# Meth# NCR#
n 435 429 419 420 436
1.1 All 25 (8%) 21 (7%) 130 (41%) 89 (28%) 49 (16%)
Cardiac Disorders Class Totals 1 (5%) 0 6 (27%) 13 (59%) 2 (9%)
Dizziness 1 5 13 0
Gastrointestinal disorders Class Totals 1 (5%) 1 (5%) 14 (70%) 0 4 (20%)
Nausea 1 5 1
Retching 1 4
General disorders and administration site 
concerns
Class Totals 1 (4%) 0 24 (86%) 3 (11%) 0
Burning sensation mucosal 9
Feeling jittery 6 2
Nervous system disorders Class Totals 4 (20%) 2 (10%) 6 (30%) 4 (20%) 4 (20%)
Headache 2 1 5 4 4
Respiratory, thoracic and mediastinal disorders Class Totals 12 (6%) 11 (6%) 73 (39%) 66 (36%) 23 (12%)
Chest discomfort 3 1 13 18 1
Cough 2 1 9 8 4
Dyspnoea 4 3 12 22 1
Nasal congestion 1 4 3
Pharyngolaryngeal pain 1 11 1 1
Reversible airways obstruction 1 3 2
Rhinitis 3 1 1
Rhinorrhea 2 8 1
Wheezing 1 6 7 1
#Exc = Exercise; Mann = Mannitol; Meth = Methacholine; NCR = not challenge relatedRespiratory Research 2009, 10:4 http://respiratory-research.com/content/10/1/4
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ratory physician assign a diagnosis at Visit 5 on the basis
of having all the information (including the exercise test
results) except the results of the methacholine and manni-
tol tests. The information available was likely to be more
than most clinicians would have available at assessment
and thus as close to a clinical gold standard as one is likely
to find. There was good agreement (71.6%) with the exer-
cise test result and ClinDx5+ diagnosis of asthma with
only 14 subjects positive to exercise being considered not
to have asthma (ClinDx5-). This supports the fact that
BHR to exercise, i.e. EIB, is accepted by clinicians as con-
sistent with a diagnosis of asthma. The agreement
between a ClinDx5 diagnosis and the methacholine result
was 59.6% and mannitol was 61.8%.
In the Phase 3 study on mannitol, in subjects with known
asthma and healthy subjects without asthma, the specifi-
city and sensitivity of mannitol to identify a clinical diag-
nosis of asthma was 59.8% and 95.2% and it was 88.7%
and 95% when those with a negative mannitol test being
treated with inhaled corticosteroids were excluded [7]. In
this study in subjects with symptoms but without a defi-
nite diagnosis of asthma at entry mannitol had a sensitiv-
ity and specificity of 56% and 73% and this was no
different to methacholine 51% and 75%.
In conclusion, mannitol and methacholine provided ther-
apeutic equivalence to identify BHR, EIB, and a clinical
diagnosis of asthma in a group of subjects suspected of
having asthma but without a clear diagnosis. While man-
nitol has potential to replace other challenges for BPT, any
of these tests can provide specific information and insight
regarding mechanism in a particular patient.
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